Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 6/20 | 0.62 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31261698 | 1.00 | NR1H3 (0.62) | NR1H3NR1H2POLBMGLLCASP1 | |
| SCHEMBL28621994 | 0.84 | NR1H2 (0.46) | NR1H3NR1H2MGLLBCHECES1 | |
| SCHEMBL9665968 | 0.81 | NR1H2 (0.62) | NR1H3NR1H2POLBMGLLCASP1 | |
| SCHEMBL4649466 | 0.79 | POLB (0.65) | NR1H3NR1H2POLBCASP1BCHE | |
| SCHEMBL29048452 | 0.78 | NR1H3 (0.58) | NR1H3NR1H2POLBMGLLCASP1 | |
| SCHEMBL1904159 | 0.78 | NR1H3 (0.68) | NR1H3NR1H2POLBMGLLCASP1 | |
| SCHEMBL10460590 | 0.78 | CYP3A4 (0.46) | NR1H3NR1H2POLBMEN1KMT2A | |
| SCHEMBL29616419 | 0.77 | NR1H3 (1.00) | NR1H3NR1H2POLB | |
| SCHEMBL2464969 | 0.77 | NR1H3 (1.00) | NR1H3NR1H2POLB | |
| SCHEMBL6690679 | 0.77 | NR1H3 (0.61) | NR1H3NR1H2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686373-B2 | ANALGESICS; ANTIINFLAMMATORY AGENT | WARNER-LAMBERT COMPANY LLC | 2004-02-03 | — | — | US | disclosed |
| US-20030130277-A1 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | KAWAMURA KIYOSHI (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-1310498-A2 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | PFIZER INC. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-5053417-A | Antiulcer agents | TANABE SEIYAKU CO., LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| US-4996217-A | Antiulcer agents | TANABE SEIYAKU COMPANY, LTD. (JP) | 1991-02-26 | — | — | US | disclosed |
| EP-0213474-A2 | Substituted toluidines, process for their preparation, pharmaceutical compositions containing them and their use as gastric secretion inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130277-A1 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | PRKCB, PRKCA, PRKCG | NR1H3 2793/4885NR1H2 2176/4885POLB 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.